This study examined a gene therapy using human nerve growth factor in patients with Alzheimer's disease. People with a diagnosis of probable Alzheimer's disease in the early stage (generally within three years of onset) could take part. The study was carried out in Phase 1 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
* Neurologist certified diagnosis of probable Alzheimer's disease * Early stage of Alzheimer's disease (generally within three years of onset) * Normal speaking ability and normal ability to understand * Ability to understand the potential risks of participation in this study * Willing to visit the San Diego area and be available for many visits in the first year * Willing to discontinue use of drugs Cognex, Aricept, Exelon, or Reminyl for the first 18 months of the trial